Pulmonary Hypertension SOLAR Study
This study is looking for people aged 18 or older who are on the lung transplant waiting list at Duke University Medical Center and have pulmonary hypertension (high blood pressure in the lungs) due to interstitial lung disease (scarring of the lungs) or COPD (chronic obstructive pulmonary disease). The goal is to find a unique pattern using hyperpolarized 129Xe (xenon gas) magnetic resonance imaging (129Xe MRI) that shows how blood vessels in the lungs are changing. This pattern could help doctors identify which patients with Group 3 pulmonary hypertension might benefit from specific treatments. The study aims to see if this pattern matches changes seen in lung tissue after transplant. This research could help predict how patients will respond to treatments in the future.
- Study design
- This interventional study plans to enroll 30 participants. It is not specified if it is randomized or blinded.
- What's involved
- Participants will receive a dose of hyperpolarized 129Xe gas for the MRI. The primary endpoint is measured at Day 1.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint is measured at Day 1, but further follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pulmonary Hypertension SOLAR
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sudarshan Rajagopal, MD, PhD · PRINCIPAL_INVESTIGATOR · Duke University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- a pathology-based 129Xe MRI noninvasive signature of pulmonary vascular remodeling that could be validated in a larger cohort of Group 3 PH patientsDay 1
Such a signature could then be tested in clinical trials in Group 3 PH. These studies will have an important positive impact because they lay the foundation for a precision medicine strategy in Group 3 PH through the identification of potential responders and non-responders to PAH-specific therapies